• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»biotech partnerships

What the Senhwa Biosciences and CellType collaboration reveals about AI’s role in oncology pipelines

By Pallavi Madhiraju on March 8, 2026   Pharma & Biotech  

What the Senhwa Biosciences and CellType collaboration reveals about AI’s role in oncology pipelines

Senhwa Biosciences and CellType partner to advance silmitasertib with AI. Discover how the collaboration could reshape immunotherapy research.

Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development

By Pallavi Madhiraju on January 28, 2026   Pharma & Biotech  

Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development

Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.

Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences

By Pallavi Madhiraju on January 19, 2026   Pharma & Biotech  

Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences

Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes